WO2000015217A1 - A new composition - Google Patents
A new composition Download PDFInfo
- Publication number
- WO2000015217A1 WO2000015217A1 PCT/SE1999/001596 SE9901596W WO0015217A1 WO 2000015217 A1 WO2000015217 A1 WO 2000015217A1 SE 9901596 W SE9901596 W SE 9901596W WO 0015217 A1 WO0015217 A1 WO 0015217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- component
- pharmaceutical formulation
- composition
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to a composition which comprises a first component (a) which is (7 ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l-benzopyran-5- carboxamide hydrogen (2i?,3i?)-tartrate monohydrate and a second component (b) which is a 5- ⁇ T reuptake inhibitor excluding citalopram and paroxetine.
- the present invention also relates to a process for the preparation of the inventive composition, pharmaceutical formulations containing said composition and to the use of said composition either by concomitant administration or by separate administration as an improvement of the treatment of affective disorders such as depression, anxiety, obsessive compulsive disorder (OCD), etc.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002342223A CA2342223A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
AU63779/99A AU6377999A (en) | 1998-09-16 | 1999-09-13 | A new composition |
EP99951318A EP1113792A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
JP2000569801A JP2002524507A (en) | 1998-09-16 | 1999-09-13 | New composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9803155A SE9803155D0 (en) | 1998-09-16 | 1998-09-16 | A new composition |
SE9803155-2 | 1998-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000015217A1 true WO2000015217A1 (en) | 2000-03-23 |
Family
ID=20412626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/001596 WO2000015217A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1113792A1 (en) |
JP (1) | JP2002524507A (en) |
AU (1) | AU6377999A (en) |
CA (1) | CA2342223A1 (en) |
SE (1) | SE9803155D0 (en) |
WO (1) | WO2000015217A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030405A2 (en) * | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
US8309107B2 (en) | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
-
1998
- 1998-09-16 SE SE9803155A patent/SE9803155D0/en unknown
-
1999
- 1999-09-13 JP JP2000569801A patent/JP2002524507A/en active Pending
- 1999-09-13 WO PCT/SE1999/001596 patent/WO2000015217A1/en not_active Application Discontinuation
- 1999-09-13 CA CA002342223A patent/CA2342223A1/en not_active Abandoned
- 1999-09-13 EP EP99951318A patent/EP1113792A1/en not_active Withdrawn
- 1999-09-13 AU AU63779/99A patent/AU6377999A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030405A2 (en) * | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
WO2002030405A3 (en) * | 2000-10-13 | 2002-09-06 | Neurosearch As | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
US7307087B2 (en) | 2000-10-13 | 2007-12-11 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
US8309107B2 (en) | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
Also Published As
Publication number | Publication date |
---|---|
AU6377999A (en) | 2000-04-03 |
CA2342223A1 (en) | 2000-03-23 |
EP1113792A1 (en) | 2001-07-11 |
JP2002524507A (en) | 2002-08-06 |
SE9803155D0 (en) | 1998-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6172105B1 (en) | Composition and methods employing it for the treatment of 5-HT-mediated disorders | |
US20090306137A1 (en) | Treatment for depressive disorders | |
JP4571485B2 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
BRPI0713733A2 (en) | methods to lessen symptoms of depression and to treat one or more psychological conditions, pharmaceutical composition and kit | |
Rampello et al. | Dopamine and depression: Therapeutic implications | |
US6472423B1 (en) | Pharmaceutical composition | |
WO2000015219A1 (en) | A new composition | |
EP1113792A1 (en) | A new composition | |
AU6378299A (en) | A new composition | |
MXPA04012693A (en) | Combination therapy wherein a serotonin reuptake inhibitor is used. | |
ZA200101946B (en) | A new composition. | |
JP4571645B2 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
CA2537747A1 (en) | The combination of a serotonin reuptake inhibitor and loxapine | |
JP2002511408A (en) | New treatments for neurological disorders | |
MXPA01002543A (en) | A new composition | |
KR20060124639A (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
KR20010086459A (en) | Use of a 5HT2A and 5HT2A/C Receptor Antagonist for Preparing Medicines for Treating Snoring and High Resistance Syndrome of Upper Anatomical Airways | |
MXPA01002370A (en) | A new composition | |
Owen | Psychotropic drugs are commonly employed in the management of patients who are medically ill. At least 35% of psychiatric consultations include recommendations for medication (Bronheim et al. 1998). The appropriate use of psychopharmacology in medically ill patients requires careful consideration of the underlying medical | |
ZA200409278B (en) | Combination therapy wherein a serotonin reuptake inhibitor is used |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 63779 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 63779/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2342223 Country of ref document: CA Ref country code: CA Ref document number: 2342223 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 569801 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951318 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951318 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951318 Country of ref document: EP |